Acetylcholine Receptor Binding Antibody with reflex to Muscle-Specific Kinase (MuSK) Ab, IgG
Also known as: ACHR BIN R
Use
Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibodies can activate complement and lead to loss of AChR, while blocking antibodies may impair the binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibodies cause receptor endocytosis, resulting in loss of AChR expression and correlating most closely with the clinical severity of the disease. This test is intended as an initial diagnostic test when suspicion of myasthenia gravis is high.
Special Instructions
Not provided.
Limitations
The test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. It is performed in a CLIA certified laboratory and is intended for clinical purposes. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.
New York Approved
Methodology
Immunoassay (RIA)
Biomarkers
LOINC Codes
- 11034-6 - AChR Bind Ab Ser-sCnc
Result Turnaround Time
2-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.3 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate from cells ASAP or within 2 hours of collection.
Storage Instructions
Refrigerated.
Causes for Rejection
Plasma. Contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month (avoid repeated freeze/thaw cycles) |
Other tests from different labs that may be relevant